Remarkably, the inclusion of exon 40.2 (as determined by the high PSI value of this event) seems to be a common hallmark of tumor pathologies, including HCC, as demonstrated by analysis of this splicing event in different tumors (tumor vs. normal tissue) in the TCGA SpliceSeq database, in which FN1 exon 40.2 exhibited a higher PSI (a higher percentage of presence) in different types of cancer tissues compared to normal tissues (Supplementary Fig. 3c). This evidence concerns the gene FN1 and cancer.